[{"id":"cf042111-c026-42d8-bfbb-bbf21966b009","acronym":"","url":"https://clinicaltrials.gov/study/NCT03682744","created_at":"2021-01-18T18:03:27.452Z","updated_at":"2024-07-02T16:36:13.862Z","phase":"Phase 1","brief_title":"CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)","source_id_and_acronym":"NCT03682744","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2022-04-06"},{"id":"93f87e57-9718-4f29-b02f-982fc7f27fd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04037241","created_at":"2021-01-18T19:48:33.373Z","updated_at":"2024-07-02T16:36:14.266Z","phase":"Phase 2b","brief_title":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer \u0026 Liver Metastases","source_id_and_acronym":"NCT04037241","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • gene-modified anti-CEA T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2022-04-01"},{"id":"6057d5a5-8252-4e03-8807-9ee477a97a89","acronym":"HITM-SURE","url":"https://clinicaltrials.gov/study/NCT02850536","created_at":"2021-01-18T13:59:34.702Z","updated_at":"2024-07-02T16:36:22.633Z","phase":"Phase 1","brief_title":"CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer","source_id_and_acronym":"NCT02850536 - HITM-SURE","lead_sponsor":"Roger Williams Medical Center","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 02/01/2017","start_date":" 02/01/2017","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 09/17/2021","study_completion_date":" 09/17/2021","last_update_posted":"2021-10-21"},{"id":"afd5a8c4-3496-4ed3-a4ba-c4c144e184fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT00673829","created_at":"2021-01-18T02:31:03.825Z","updated_at":"2024-07-02T16:37:31.244Z","phase":"Phase 1a/1b","brief_title":"Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer","source_id_and_acronym":"NCT00673829","lead_sponsor":"Roger Williams Medical Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Suspended","enrollment":" Enrollment 26","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-06-17"}]